Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org February 9, 2026 preprint DOI: 10.20944/preprints202602.0590.v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Interventions | 5-MeO-DMT THCV |
| Topics | Anxiety Neuroplasticity 5-MeO-DMT Depression DMT |
| Keywords | Antidepressant Depression economics Anxiolytic Imipramine |
| Key points | Proposes that co-administering 5-MeO-DMT and THCV via a precision vaporization device may provide a more effective and tolerable treatment for Treatment-Resistant Depression and anxiety disorders by leveraging the neuroplastic benefits of the tryptamine within a cannabinoid-mediated anxiolytic "cushion." |
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatments like SSRIs, SNRIs, and TCAs often require weeks for efficacy and do not address synaptic atrophy or the rapid "reset" of the Default Mode Network (DMN) required for immediate relief. While 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shows rapid antidepressant effects, its intensity often triggers panic responses. In contrast, Tetrahydrocannabivarin (THCV) has demonstrated anxiolytic properties without significant psychoactivity at lower doses. The present work describes a novel approach via a precision vaporization device that co-administers a specific ratio of 5-MeO-DMT and THCV. This is designed to allow the neuroplastic benefits of the tryptamine to occur within a "cushion" of cannabinoid-mediated anxiolysis, preventing the acute activity increase and panic often observed with high-potency psychedelics. This synergistic combination offers potential for a more effective and tolerable treatment for TRD and anxiety disorders, leveraging the distinct properties of 5-MeO-DMT and THCV.